A multi-centre study of therapeutic efficacy and safety of platelet components treated with amotosalen and ultraviolet A pathogen inactivation stored for 6 or 7 d prior to transfusion-Reference-Cited by-同舟云学术

A multi-centre study of therapeutic efficacy and safety of platelet components treated with amotosalen and ultraviolet A pathogen inactivation stored for 6 or 7 d prior to transfusion

Published:2011-03-21 Issue:3 Volume:153 Page:393-401
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:

Author:

Lozano Miguel,Knutson Folke,Tardivel René,Cid Joan,Maymó Rosa Maria,Löf Helena,Roddie Huw,Pelly Jane,Docherty Anthony,Sherman Claire,Lin Lily,Propst Meisa,Corash Laurence,Prowse Chris

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2141.2011.08635.x/fullpdf

Reference31 articles.

1. Factors influencing 20-hour increments after platelet transfusion;Bishop;Transfusion,1991

2. Early recognition and reporting of suspected bacterial contamination may prevent transfusion transmission of infection by associated units;Cawley;Transfusion Medicine,2011

3. An active hemovigilance program characterizing the safety profile of 7483 transfusions with plasma components prepared with amotosalen and UVA photochemical treatment;Cazenave;Transfusion,2010

4. Release of immune modulation factors from platelet concentrates during storage after photochemical pathogen inactivation treatment;Cognasse;Transfusion,2008

5. Corrected count increment and percent platelet recovery as measures of posttransfusion platelet response: problems and a solution;Davis;Transfusion,1999

Cited by 105 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Platelet Pathogen Reduction Technology—Should We Stay or Should We Go…?;Journal of Clinical Medicine;2024-09-10

2. Results of clinical effectiveness of conventional versus Mirasol‐treated Apheresis Platelets in Patients with Hypoproliferative Thrombocytopenia (MiPLATE) trial;Transfusion;2024-02-05

3. Therapeutic efficacy and safety of pathogen‐reduced platelet components: Results of a meta‐analysis of randomized controlled trials;Vox Sanguinis;2024-01-05

4. Therapeutic efficacy of platelet transfusion treated with amotosalen/UVA pathogen inactivation technology (INTERCEPT ^TMBlood System) in acute myeloid leukemia patients undergoing chemotherapy with curative intent: a single center experience;BLOOD TRANSFUS-ITALY;2023

5. Biochemical and functional characteristics of stored (double‐dose) buffy‐coat platelet concentrates treated with amotosalen and a prototype UVA light‐emitting diode illuminator;Transfusion;2023-08-24